跳至主要内容
临床试验/ACTRN12613000862741
ACTRN12613000862741尚未招募4 期

In critically ill patients infected with extensively drug resistant Acinetobacter baumanii (XDRAb), does the use of colistin loading dose compared to the normal maintenance of colistin has better 30 day mortality outcome?

Helmi B Sulaiman0 个研究点目标入组 100 人开始时间: 2013年8月5日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1)Age 18 and above
  • 2)Patients with a first episode of culture proven XDRAb from blood, CSF, sputum and tracheal aspirate samples.
  • 3)Receive colistin treatment for more than 72 hours
  • 4)Fulfill diagnostic criteria for ventilator-related pneumonia, hospital-acquired pneumonia, bacteremia (catheter- and non catheter-related), and meningitis or CSF infections, as defined in accordance with IDSA guidelines

排除标准

  • 1) Pregnant
  • 2) Breastfeeding
  • 3) ALT/AST more than 8 times upper limit of normal
  • 5) Allergy to colistin or its prodrug

研究者

发起方
Helmi B Sulaiman

相似试验